Results 21 to 30 of about 243,764 (341)

Hyperprolactinemia as a side effect of using antipsychotics In Schizophrenic Patients

Jurnal Psikiatri Surabaya, 2023
Introductions: Antipsychotics are still the mainstay of schizophrenia management. Antipsychotics are antagonistic to postsynaptic dopamine receptors in the brain.
Syaiful Anwar, Khairina
doaj   +1 more source

The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients [PDF]

, 2008
We investigated the relationships between functional genetic variants of the 5-HT(2C) receptor and multidrug-resistant protein (MDR1), coding for P-glycoprotein, and second generation antipsychotic (SDA)-induced weight gain among 108 female schizophrenic
Bilušić, Hrvoje, Božina, Nada, Hotujac, Ljubomir, Medved, Vesna, Rojnić Kuzman, Martina, Šain, Ivica   +5 more
core   +1 more source

Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments

BMC Psychiatry, 2022
Background Antipsychotic drugs are associated with adverse events, but serious side effects are not frequent. This study aimed to ascertain whether previous exposure to antipsychotic treatment was associated with metabolic disturbances induced by current
Ye Yang, Peng Xie, Yujun Long, Jing Huang, Jingmei Xiao, Jingping Zhao, Weihua Yue, Renrong Wu   +7 more
doaj   +1 more source

Incidence and drug treatment of emotional distress after cancer diagnosis : a matched primary care case-control study [PDF]

, 2012
Notes This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.Peer ...
A J Lee, C Bond, C Burton, C Burton, DR Cox, E Martin-Merino, F Desplenter, F Hansen, G Laekeman, G Rait, J Madden, JC Holland, JL Roffman, K Lefevre, KC Yung, L Hodges, M Miovic, M Sharpe, M Vahdaninia, M Watson, MB First, MJ Massie, NF Khan, P Lockhart, P Murchie, PP Roy-Byrne, R Morris, R Munoz-Arroyo, RA Lewis, S Simoens, S Wein, SB Patten, TL Deshields, V Strong   +33 more
core   +1 more source

Antipsychotic Polypharmacy and High-Dose Antipsychotic Regimens in the Residential Italian Forensic Psychiatric Population (REMS)

Frontiers in Psychology, 2022
Few data exist regarding treatment with antipsychotics in forensic psychiatric patient populations with high social dangerousness. We performed a secondary analysis of 681 patients treated with at least one antipsychotic, extracted from a 1-year ...
Gabriele Mandarelli, Felice Carabellese, Guido Di Sciascio, Roberto Catanesi   +3 more
doaj   +1 more source

Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia

JAMA Network Open, 2019
Key Points Question Which atypical antipsychotic is most beneficial and safe for the treatment of behavioral and psychological symptoms of dementia? Findings In this network meta-analysis of 17 studies (5373 patients), no significant differences were ...
Ismaeel Yunusa, A. Alsumali, Asabe E. Garba, Q. Regestein, T. Eguale   +4 more
semanticscholar   +1 more source

Prescriptions of Antipsychotics in Younger and Older Geriatric Patients with Polypharmacy, Their Safety, and the Impact of a Pharmaceutical-Medical Dialogue on Antipsychotic Use

Biomedicines, 2022
Geriatric patients are a particularly vulnerable and, at the same time, very heterogeneous group due to their multimorbidity and polypharmacy. Antipsychotics are often prescribed in their complex drug regimens, whereby the prescription of antipsychotics ...
Eva-Maria Gebauer, Albert Lukas
doaj   +1 more source

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomised controlled treatment trials [PDF]

, 2006
Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive–compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory.
Carey, P, Denys, D, Fineberg, N, Premkumar, P, Seedat, S, Sivakumaran, T, Stein, DJ, Vythilingum, B, Westenberg, H   +8 more
core   +1 more source

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Therapeutics and Clinical Risk Management, 2017
Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to ...
M. Solmi, A. Murru, I. Pacchiarotti, J. Undurraga, N. Veronese, M. Fornaro, B. Stubbs, Francesco Monaco, E. Vieta, M. Seeman, C. Correll, A. Carvalho   +11 more
semanticscholar   +1 more source

Symptomatic treatment of children with anti-NMDAR encephalitis. [PDF]

, 2016
AIM: We performed the first study on the perceived benefit and adverse effects of symptomatic management in children with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis.
Brilot, F, Dale, R. C., Hong, M, Jones, H, Mohammad, Ss, Nosadini, M, Pillai, Sc, Sharpe, C   +7 more
core   +1 more source